Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Exploring Factors Related to Metastasis Free Survival in Breast Cancer Patients Using Bayesian Cure Models

  • Jafari-Koshki, Tohid (Department of Biostatistics, School of Health, Sabzevar University of Medical Sciences) ;
  • Mansourian, Marjan (Department of Biostatistics and Epidemiology, Health School, Isfahan University of Medical Sciences) ;
  • Mokarian, Fariborz (Cancer Prevention Research Center, Isfahan University of Medical Sciences)
  • Published : 2014.12.18
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Breast cancer is a fatal disease and the most frequently diagnosed cancer in women with an increasing pattern worldwide. The burden is mostly attributed to metastatic cancers that occur in one-third of patients and the treatments are palliative. It is of great interest to determine factors affecting time from cancer diagnosis to secondary metastasis. Materials and Methods: Cure rate models assume a Poisson distribution for the number of unobservable metastatic-component cells that are completely deleted from the non-metastasis patient body but some may remain and result in metastasis. Time to metastasis is defined as a function of the number of these cells and the time for each cell to develop a detectable sign of metastasis. Covariates are introduced to the model via the rate of metastatic-component cells. We used non-mixture cure rate models with Weibull and log-logistic distributions in a Bayesian setting to assess the relationship between metastasis free survival and covariates. Results: The median of metastasis free survival was 76.9 months. Various models showed that from covariates in the study, lymph node involvement ratio and being progesterone receptor positive were significant, with an adverse and a beneficial effect on metastasis free survival, respectively. The estimated fraction of patients cured from metastasis was almost 48%. The Weibull model had a slightly better performance than log-logistic. Conclusions: Cure rate models are popular in survival studies and outperform other models under certain conditions. We explored the prognostic factors of metastatic breast cancer from a different viewpoint. In this study, metastasis sites were analyzed all together. Conducting similar studies in a larger sample of cancer patients as well as evaluating the prognostic value of covariates in metastasis to each site separately are recommended.

Keywords

References

  1. Altundag K, Bondy ML, Mirza NQ, et al (2007). Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system Metastasis. Cancer, 110, 2640-7. https://doi.org/10.1002/cncr.23088
  2. American Cancer Society (2011). Global cancer facts & figures 2nd edition; estimated number of new cancer cases by World Area, 2008.
  3. Andre F, Slimane K, Bachelot T, et al (2004). Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Ontol, 22, 3302-8. https://doi.org/10.1200/JCO.2004.08.095
  4. Babu GR, Samari G, Cohen SP, et al (2011). Breast cancer screening among females in Iran and recommendations for improved practice. Asian Pac J Cancer Prev, 12, 1647-55.
  5. Balleine R, Earl M, Greenberg M, et al (1999). Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer, 79, 1564-71. https://doi.org/10.1038/sj.bjc.6690249
  6. Basu S, Tiwari RC (2010). Breast cancer survival, competing risks and mixture cure model: a Bayesian analysis. J Royal Statist Soc, 173, 307-29. https://doi.org/10.1111/j.1467-985X.2009.00618.x
  7. Carter C, Allen C, Henson D (1989). Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer, 63, 181-7. https://doi.org/10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
  8. Chen M-H, Ibrahim JG, Sinha D (1999). A new bayesian model for survival data with a surviving fraction. J Am Statistical Association, 94, 909-19. https://doi.org/10.1080/01621459.1999.10474196
  9. Colleoni M, Rotmensz N, Peruzzotti G, et al (2005). Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol, 23.
  10. Congdon PD 2010. Applied bayesian hierarchical methods, chapman & hall/CRC.
  11. Eichler AF, Kuter I, Ryan P, et al (2008). Survival in patients with brain metastases from breast cancer. Cancer, 112, 2359-67. https://doi.org/10.1002/cncr.23468
  12. Evans AJ, James JJ, Cornford EJ, et al (2004). Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol, 16, 345-9. https://doi.org/10.1016/j.clon.2004.03.012
  13. Foster TS, Miller JD, Boye ME, et al (2011). The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treat Rev, 37, 405-15.
  14. Gao D, Du J, Cong L, et al (2009). Risk factors for initial lung metastasis from breast invasive ductal carcinoma in stages i-iii of operable patients. Jpn J Clin Oncol, 39, 97-104.
  15. Garcia M, Platet N, Liaudet E, et al (1996). Biological and clinical significance of cathepsin d in breast cancer Metastasis. Stem Cells, 14, 642-50. https://doi.org/10.1002/stem.140642
  16. Ibrahim JG, Chen M-H, Sinha D (2001). Bayesian survival analysis, springer-verlag New York.
  17. Inoue H, Kawada A, Takasu H, et al (1998). Cathepsin D expression in skin metastasis of breast cancer. J Cutaneous Pathology, 25, 365-9. https://doi.org/10.1111/j.1600-0560.1998.tb01759.x
  18. Jemal A, Bray F, Center MM, et al (2011). Global Cancer Statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  19. Johnston SRD (2010). Living with secondary breast cancer: coping with an uncertain future with unmet needs. European J Cancer Care, 19, 561-3. https://doi.org/10.1111/j.1365-2354.2010.01216.x
  20. Koizumi M, Yoshimoto M, Kasumi F, et al (2010). An open cohort study of bone metastasis incidence following surgery in breast cancer patients. BMC Cancer, 10, 381. https://doi.org/10.1186/1471-2407-10-381
  21. Koscielny S, Tubiana M, Le M, et al (1984). Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer, 49, 709-15. https://doi.org/10.1038/bjc.1984.112
  22. Lamyian M, Hydarnia A, Ahmadi F, et al (2007). Barriers to and factors facilitating breast cancer screening among Iranian women: a qualitative study. East Med Health J, 13, 1160-9.
  23. Largillier R, Ferrero J-M, Doyen J, et al (2008). Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol, 19, 2012-9. https://doi.org/10.1093/annonc/mdn424
  24. Lunn D, Spiegelhalter D, Thomas A, et al (2009). The BUGS project: Evolution, critique, and future directions. Statistics in Medicine, 28, 3049-67. https://doi.org/10.1002/sim.3680
  25. Mayer M, Hunis A, Oratz R, et al (2010). Living with metastatic breast cancer: a global patient survey. Community Oncology, 7, 406-12. https://doi.org/10.1016/S1548-5315(11)70415-6
  26. Minisini AM, Moroso S, Gerratana L, et al (2013). Risk factors and survival outcomes in patients with brain metastases from breast cancer. clinical and experimental metastasis.
  27. Montazeri A, Vahdaninia M, Harirchi I, et al (2008). Breast cancer in Iran: need for greater women awareness of warning signs and effective screening methods. Asia Pac Family Medicine, 7.
  28. Morris PG, Murphy CG, Mallam D, et al (2012). Limited overall survival in patients with brain metastases from triple negative breast cancer. Breast J, 1-6.
  29. Mousavi SM, Gouya MM, Ramazani R, et al (2009). Cancer incidence and mortality in Iran. Ann Oncol, 20, 556-63.
  30. Mousavi SM, Montazeri A, Mohagheghi MA, et al (2007). Breast cancer in Iran: an epidemiological review. Breast J, 13, 383-91. https://doi.org/10.1111/j.1524-4741.2007.00446.x
  31. Nieder C, Marienhagenz K, Thammx R, et al (2008). Prediction of very short survival in patients with brain metastases from breast cancer. Clin Oncol, 20, 337-9. https://doi.org/10.1016/j.clon.2008.03.005
  32. Noroozi A, Jomand T, Tahmasebi R (2011). Determinants of breast self-examination performance among iranian women: an application of the health belief model. J Canc Educ, 26, 365-74. https://doi.org/10.1007/s13187-010-0158-y
  33. Oltean D, Dicu T, Eniu D (2009). Brain metastases secondary to breast cancer: symptoms, prognosis and evolution. Tumori, 95, 697-701.
  34. Othus M, Barlogie B, LeBlanc ML (2012a). Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res.
  35. Othus M, Barlogie B, LeBlanc ML, et al (2012b). Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res, 18, 3731-6. https://doi.org/10.1158/1078-0432.CCR-11-2859
  36. Palmieria D, Smithb QR, Lockmanb PR, et al (2006, 2007). Brain metastases of breast cancer. Breast Disease, 26, 139-47.
  37. Rama R, Swaminathan R, Venkatesan P (2010). Cure models for estimating hospital-based breast cancer survival. Asian Pac J Cancer Prev, 11, 387-91.
  38. Rochefort H, Capony F, Garcia M (1990). Cathepsin D: A protease involved in breast cancer metastasis. Cancer Metastasis Reviews, 9, 321-31. https://doi.org/10.1007/BF00049522
  39. Rochefort H, Liaudent-coopman E (1999). Cathepsin D in cancer metastasis: A protease and a ligand. APMIS, 107, 86-95. https://doi.org/10.1111/j.1699-0463.1999.tb01530.x
  40. Ruiterkamp J, Ernst MF, de Munck L, et al (2011). Improved survival of patients with primary distant metastatic breast cancer in the period of 1995-2008. Breast Cancer Res Treat, 128, 495-503. https://doi.org/10.1007/s10549-011-1349-x
  41. Santen G, Danhof M, Della Pasqua O (2008). Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model. J Psychiatric Res, 42, 1189-97. https://doi.org/10.1016/j.jpsychires.2007.11.009
  42. Selzner M, Morse MA, Vredenburgh JJ, et al (2000). Liver metastases from breast cancer: long-term survival after curative resection. Surgery, 127, 383-9. https://doi.org/10.1067/msy.2000.103883
  43. Senkus E, Cardoso F, Pagani O (2013). Time for more optimism in metastatic breast cancer? Cancer Treatment Reviews, 40, 220-8.
  44. Sezgin C, Gokmen E, Esassolak M, et al (2007). Risk factors for central nervous system metastasis in patients with metastatic breast cancer. Medical Oncology, 24, 155-61. https://doi.org/10.1007/BF02698034
  45. Sposto R (2002). Cure model analysis in cancer: an application to data from the children's cancer group. Statist Med, 21, 293-312. https://doi.org/10.1002/sim.987
  46. Taghavi A, Fazeli Z, Vahedi M, et al (2012). Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev, 13, 367-70. https://doi.org/10.7314/APJCP.2012.13.1.367
  47. Truong PT, Berthelet E, Lee J, et al (2005). The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer, 103, 2006-14. https://doi.org/10.1002/cncr.20969
  48. Van Der Wal Bch, Butzelaar Rmjm, Van Der Meij S, et al (2002). Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol, 28, 481-9. https://doi.org/10.1053/ejso.2002.1239
  49. Veronesi U, Galimberti V, Zurrida S, et al (1993). Prognostic significance of number and level of axillary node metastases in breast cancer. The Breast, 2, 224-8. https://doi.org/10.1016/0960-9776(93)90004-Y
  50. Voogd AC, Cranenbroek S, de Boer R, et al (2005). Long-term prognosis of patients with axillary recurrence after axillary dissection for invasive breast cancer. European Journal of Surgical Oncol, 31, 485-9. https://doi.org/10.1016/j.ejso.2004.12.017
  51. Wadasadawala T, Gupta S, Bagul V, et al (2007). Brain metastases from breast cancer: Management approach. Journal of Cancer Research and Therapeutics, 3, 157-65. https://doi.org/10.4103/0973-1482.37409
  52. Weigelt B, Peterse JL, van 't Veer LJ (2005). Breast Cancer Metastasis: Markers and Models. Nature Reviews, Cancer, 5, 591-602. https://doi.org/10.1038/nrc1670
  53. Yamasaki S, Okino T, Kan N, et al (1992). Factors influencing the response and survival of patients with liver metastases from breast cancer receiving OK-432-combined adoptive immunotherapy. J Cancer Res Clin Oncol, 118, 157-62. https://doi.org/10.1007/BF01187506
  54. Yin G, Ibrahim JG (2005). Cure rate models: a unified approach. Canadian J Statistics, 33, 559-70. https://doi.org/10.1002/cjs.5550330407
  55. Yu XQ, De Angelis R, Andersson TML, et al (2013). Estimating the proportion cured of cancer: Some practical advice for users. Cancer Epidemiology, 37, 936-842.

Cited by

  1. Application of a Non-Mixture Cure Rate Model for Analyzing Survival of Patients with Breast Cancer vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.7359
  2. Impact of Age, Tumor Size, Lymph Node Metastasis, Stage, Receptor Status and Menopausal Status on Overall Survival of Breast Cancer Patients in Pakistan vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1019
  3. Application of non-parametric non-mixture cure rate model for analyzing survival of patients with colorectal cancer pp.2092-7193, 2018, https://doi.org/10.4178/epih.e2018045